MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by EANES, R. Z.
Right arrow Articles by KUN, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by EANES, R. Z.
Right arrow Articles by KUN, E.

Molecular Pharmacology, Vol 10, 130-139, Copyright © 1974 by the American Society for Pharmacology and Experimental Therapeutics

Inhibition of Liver Aconitase Isozymes by (-)-erythro-Fluorocitrate

ROBERT Z. EANES 1 and ERNEST KUN 1

1 Departments of Biochemistry and Biophysics, Pharmacology, and Cardiovascular Research Institute, University of California, San Francisco, California 94143

A highly purified cytosol aconitase [citrate (isocitrate) hydrolyase, EC 4.2.1.3] was isolated from pig liver. Whereas purified aconitase preparations previously reported in the literature require cysteine and Fe2+ for maximal catalytic activity, the purified cytosol enzyme and the partially purified mitochondrial aconitase described here need no added activator. The molecular weight of the purified cytosol enzyme as determined by sucrose density gradient centrifugation was between 107,000 and 111,000. Inhibitory effects of (-)-erythro-fluorocitrate on both aconitase isoenzymes were studied in the absence and presence of Mg2+ and Mn2+. Fluorocitrate was a competitive reversible inhibitor of both aconitases, as deduced from steady-state kinetic analyses (average Ki = 22-45 µM). The bivalent cations Mg2+ and especially Mn2+, when incubated with either aconitase isoenzyme, inhibited enzymatic activity, an effect which increased with time. A high concentration (30 mM) of citrate reversed the inhibition and protected the enzyme against inhibition by Mg2+ or Mn2+. When (-)-erythro-fluorocitrate and Mg2+ (or Mn2+) were present simultaneously, as in the isocitrate dehydrogenase coupled assay system, the time-dependent inhibition which ensued was a result of competitive inhibition by fluorocitrate and the more complex inhibition of the enzyme by Mg2+ or Mn2+

Note:
ACKNOWLEDGMENT It is a pleasure to acknowledge the contribution of Miss Barbara Lancaster to the writing of the manuscript.

Submitted on August 22, 1973




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
H. Lauble, M. C. Kennedy, M. H. Emptage, H. Beinert, and C. D. Stout
The reaction of fluorocitrate with aconitase and the crystal structure of the enzyme-inhibitor complex
PNAS, November 26, 1996; 93(24): 13699 - 13703.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1974 by the American Society for Pharmacology and Experimental Therapeutics